The Phase One Foundation has awarded GIST Specialist Jason Sicklick a $500,000 grant to study GIST in a Temozolomide Phase II clinical trial.
Deb Melikian, patient advocate, and Dr. Jason Sicklick, GIST expert & researcher, share the story of their unique partnership which began at an LRG GIST Day of Learning in the rare partners issue of RARE Revolution Magazine.
Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego talks about the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.
A Pediatric & SDH-Deficient GIST Consortium Update: A Review with Experts & Advocates presented by Jayne Bressington, Becky Owens, and Dr. Jason Sicklick at New Horizons 2019 in Wayne, NJ.
Rare GIST Sub-Types presented by Dr. Jason Sicklick of Moores UCSD Cancer Center at New Horizons 2019 in Wayne, NJ.
Understanding the Concept of "Precision Oncology" in patient-friendly language presented by Dr. Jason Sicklick of Moores Cancer Center UCSD at New Horizons 2019.
Want to know more about GIST? Do you have some burning questions to ask GIST experts? Members of the LRG GIST Global Expert Surveillance Team will be at the LRG offices on May 8th at 1:00 pm [...]
State of GIST: A Clinical Panel of Experts Presented by Jason Sicklick, MD, Moores Cancer Center, University of California, San Diego; and the GIST Experts Panel - Markku Martti Miettinen, MD, National [...]
Dr. Jason Sicklick and Norman Scherzer co-present poster at 2017 CTOS meeting. Norman Scherzer, Executive Director of The Life Raft Group, recently co-presented a poster at the 2017 CTOS (Connective Tissue Oncology [...]
The Life Raft Group and UCSD hosted a three-day event at University of California, San Diego UCSD-Moores Cancer Center from July 13th through July 15th. A GIST Awareness Day (GAD) event took place on July [...]